AI English summary of an SEC filing — figures as filed
Bio-Techne TECHBio-Techne said net sales for the quarter ended June 30, 2025 increased 4% to $317.0 million, with organic revenue up 3%. Full-year net sales increased 5% to $1.2 billion, and organic revenue rose 5%.
Key points
AI summaryBio-Techne said net sales for the quarter ended June 30, 2025 increased 4% to $317.0 million, with organic revenue up 3%. Full-year net sales increased 5% to $1.2 billion, and organic revenue rose 5%.
The company said GAAP operating income for Q4 decreased to ($23.9) million from $45.8 million in the prior-year quarter, with impairment of the Exosome Diagnostics business unfavorably impacting the result. Adjusted operating income for the same quarter was $101.3 million, compared to $101.8 million in the prior-year quarter.
Bio-Techne announced the divestiture of the Exosome Diagnostics business, which met held-for-sale criteria as of June 30, 2025 and incurred an impairment loss of $83.1 million during the quarter.
The company disclosed that operating cash flow for the full year ended June 30, 2025 was 287,556 thousand, with 275,731 thousand used for share repurchases and 50,391 thousand used for cash dividends.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Q4 Net Sales $317.0 million, Full Year $1.2 billion
Bio-Techne said net sales for the quarter ended June 30, 2025 increased 4% to $317.0 million, with organic revenue up 3%. Full-year net sales increased 5% to $1.2 billion, and organic revenue rose 5%.
Source · Based on the filing body and exhibits
GAAP Operating Loss and Adjusted Operating Income
The company said GAAP operating income for Q4 decreased to ($23.9) million from $45.8 million in the prior-year quarter, with impairment of the Exosome Diagnostics business unfavorably impacting the result. Adjusted operating income for the same quarter was $101.3 million, compared to $101.8 million in the prior-year quarter.
Source · Based on the filing body and exhibits
Exosome Diagnostics Divestiture and Impairment Loss
Bio-Techne announced the divestiture of the Exosome Diagnostics business, which met held-for-sale criteria as of June 30, 2025 and incurred an impairment loss of $83.1 million during the quarter.
Source · Based on the filing body and exhibits
Full-Year Cash Flow and Share Repurchases
The company disclosed that operating cash flow for the full year ended June 30, 2025 was 287,556 thousand, with 275,731 thousand used for share repurchases and 50,391 thousand used for cash dividends.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…